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Abstract
Background: Medication overuse headache (MOH) is the third most prevalent headache type after migraine and
tension-type headache. A large number of studies on the long-term prognosis have shown that MOH has a high
relapse rate after treatment. Although MOH relapse-related risk factors have been reported, no related research has
been performed in China. Therefore, the purpose of this study was to analyze and evaluate the risk factors for MOH
relapse in China.
Methods: Eighty-six out-patients of Shandong Provincial Hospital who were initially diagnosed with MOH, and who
had successful withdrawal treatment within 2 months, were chosen from March 2012 to July 2013. All subjects
were followed up by the investigators of this study. Of the 86 subjects, 27 who had relapsed were compared with
59 who had not relapsed (i.e. the controls). Based on a standardized questionnaire, a database was created (with
Microsoft Excel 2010). The data, which included 38 indexes, were analyzed by univariate analysis with chi-square
test, Fisher’s exact test, t-test, or paired rank test. The statistically correlated (P < 0.05) variables were chosen as the
independent variables, thereby enabling the calculation of the non-conditional multivariate stepwise logistic
regression.
Results: The independent risk factors for medication-overuse headache relapse were determined as headache
frequency before drug withdrawal, duration of primary headache, and headache frequency after drug withdrawal.
Conclusion: Headache frequency before drug withdrawal, duration of primary headache, and headache frequency
after drug withdrawal may be the independent risk factors for MOH relapse in China.
Keywords: Medication-overuse headache, Relapse, Risk factors, Non-conditional multivariate stepwise logistic
regression
Background
Medication overuse headache (MOH) refers to headache
occurring on 15 or more days per month and developing
as a consequence of regular overuse of acute or symp-
tomatic headache medication (on at least 10 or 15 days
per month, depending on the medication) for more than
3 months. MOH usually resolves after the overuse has
stopped [1]. MOH usually occurs in patients who have a
history of primary headache, especially in patients with
previous history or family history of migraine and in pa-
tients with frequent headache [2].
Recent studies have shown that MOH is the third
most prevalent headache type, coming after migraine
and tension-type headache [3]. These studies have also re-
vealed an age-related involvement of MOH, even during
childhood [4]. There is no large-scale epidemiological
data on MOH in China. Dong [5] retrospectively ana-
lyzed the clinical features of 240 patients with MOH
and discovered only two patients (0.8 %) had previ-
ously been given the diagnosis of MOH. Furthermore,
the median time to diagnosis after the estimated on-
set of the disorder was 4.0 years. Therefore, MOH
has rarely been diagnosed in China. The goal of
MOH treatment is to withdraw the overuse of medi-
cation, reduce the extent and frequency of headache
attacks, and prevent relapse [6]. Many studies con-
sider the success criteria for MOH withdrawal as an
improvement in MOH relapse. A large number of stud-
ies on the long-term prognosis of MOH showed that
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this disorder has a high relapse rate after treatment. In
the first year after withdrawal, the relapse rate is the
highest—between 22 and 44 % [7]. Although MOH
relapse-related risk factors have been reported, no re-
lated research has been performed in China. Therefore,
the current study aimed to investigate the risk factors
for MOH relapse in China.
Methods
Research objective
Case Source: Eighty-six patients visiting headache spe-
cialists in the out-patient clinic of Shandong Provincial
Hospital between March 2012 and July 2013, diagnosed
with MOH for the first time, and with successful com-
pletion of the withdrawal treatment after 2 months were
invited to answer a questionnaire. They were then moni-
tored for 7.5 months. Patients with relapse were assigned
to the case group, and those without relapse were assigned
to the control group. The study was approved by the Ethic
Committee of Shandong Provincial Hospital, and written
inform consent was obtained from the participants after
they became acquainted with all the procedures (reference
number: 20140321).
Case inclusion criteria: (1) Meet the diagnostic cri-
teria for MOH: Patients should meet the 2013 Inter-
national Classification of Headache Disorders, 3rd
edition (ICHD-3) [1]. The ICHD-3 included the fol-
lowing: (A) Headache occurring on ≥15 days/month
in a patient with a pre-existing headache disorder, (B)
Regular overuse for ≥3 months of one or more drugs
that can be taken for acute and/or symptomatic treat-
ment of headache, and (C) Not better accounted for
by another ICHD-3 diagnosis; (2) Headache exacerbated
during medication-overuse; (3) No history of drug with-
drawal; (4) No obvious organic complications; (5) Meet
the criteria of successful completion of drug withdrawal
(headache completely disappears or the number of
headache days reduces by 50 % per month); (6) Meet
the MOH relapse diagnostic criteria (ICHD-IIR)
amended by the International Headache Society in
2006. Case exclusion criteria: (1) Patients with other
types of secondary headaches; (2) Patients who refuse
to enroll in the follow-up investigation; (3) Patients
with other diseases requiring long-term use of pain
medications; (4) Patients with other serious chronic dis-
eases; (5) Patients whose medical records are incomplete.
Questionnaire content and method
All patients were surveyed using a uniform questionnaire
(a database was created using Excel 2010). The survey
contents included the following: (1) Name, gender, age,
education, occupation, average annual household income,
marital status, place of residence, history of heavy smoking
and drinking, history of caffeine consumption, other drugs
and substances addiction, family history of headache, fam-
ily history of MOH, and family history of other drugs and
substance abuse; (2) Time for overuse of drugs, head-
ache frequency (days/month), degree of headache
(assessed by “pain score caliper” using the visual analog
scale [VAS] in which 0 = no pain, 10 = severe pain), and
duration of each attack before drug withdrawal; (3) The
primary headache type, primary headache course, pri-
mary headache frequency (days/month), duration of
each primary headache attack, and degree of primary
headache (VAS score); (4) The types of overused drugs, in-
cluding a single use of non-steroidal anti-inflammatory
drug (NSAID) analgesics, Chinese patent medicine,
benzodiazepine compound analgesics or a combination
of analgesics; (5) Frequency of drug use per month
(days/month), headache frequency after drug with-
drawal (days/month), duration of each attack after with-
drawal, and degree of headache after withdrawal (VAS
score); (6) Coexisting disorders such as anxiety, de-
pression (diagnostic criteria for both is found in the
American psychiatric diagnostic and statistical man-
ual, 4th edition) [8], sleep disorders, and other dis-
comfort; (7) Preventive medicine and the time taken
for the application of preventive medicine. Investiga-
tors determined a patient’s relapse by outpatient ap-
pointment or telephone follow-up, according to the
relapse criteria of the ICHD-IIR. Patients were divided
into the case group and the control group. Investiga-
tions of the contents of the 38 qualifications were
completed according to the original headache medical
records and telephone follow-up of patients and were
processed by a unified digital coding method.
Statistical analysis
Count data (such as demographics) were analyzed by the
chi-square test or Fisher’s exact test. The t-test was used
to determine the normal distribution, and the Wilcoxon
test was used to determine the skewed distribution of the
data. For the multivariate logistic regression analysis, sta-
tistically significant (P < 0.05) variables were elected as in-
dependent variables and took a significance level of α =
0.05. All data were analyzed using Statistical Product and
Service Solutions (SPSS) 17.0 software (IBM Company,
Chicago, Illinois in the United State).
Results
General basic data analysis
Data from the 86 patients (aged 18–66 years; mean:
43.4 ± 10.8 years) revealed 13 (15.1 %) cases of MOH
for males and 73 (84.9 %) cases for females. Overall,
primary headache and tension-type headache occurred in
80 (93 %) and six (7 %) patients respectively. Overused
acute medication, such as compound analgesics, occurred
in 63 (73.3 %) patients. Twenty-three (26.7 %) patients
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took a single acute medication, including 16 individuals
that used only NSAIDs (e.g. ibuprofen, acetaminophen,
and aspirin) and six patients that only used proprietary
Chinese medicine. One patient only used benzodiaze-
pines, such as diazepam, to relieve pain.
After clinic interviews, 59 (68.6 %) patients who did not
have medication overuse phenomenon were assigned as the
control group. Based on the ICHD-IIR, 27 (31.4 %) patients
were found to have MOH relapse and thus were assigned
as the case group.
Univariate analysis
Demographic and sociological indicators
Both the case and control group comprised 27 pa-
tients (31 to 65 years; mean: 46.6 years ± 10.8 years)
and 59 patients (18 to 66 years; mean: 42.0 years ±
10.6 years) respectively. The data was consistent with
a normal distribution. There was no statistical sig-
nificance between the case and control group with
respect to age, gender, education level and so on
(Table 1).
Table 1 Demographic and sociological indicators (n)
Indicators Case group (n = 27) Control group (n = 59) χ2 P
Gender Male 6 (22.2 %) 7 (11.9 %) 0.330*
Female 21 (77.8 %) 52 (88.1 %)
Education level Junior high school、primary school
or lower
17 (63.0 %) 31 (52.5 %) 0.816 0.366
Senior high school, university or
higher
10 (37.0 %) 28 (47.5 %)
Occupational status Unemployed 6 (22.2 %) 6 (10.2 %) 5.371 0.068
Student 0 (0 %) 8 (13.6 %)
Farmer 10 (37.0 %) 16 (27.1 %)
Worker 4 (14.8 %) 13 (22.0 %)
Cadre or other 7 (25.9 %) 16 (27.1 %)
Marital status Unmarried 0 (0 %) 10 (16.9 %) 5.941 0.051
Married 24 (88.9 %) 45 (76.3 %)
Divorced or widowed 3 (11.1 %) 4 (6.8 %)
Residence Rural areas and suburbs 22 (81.5 %) 38 (64.4 %) 2.560 0.110
City 5 (8.5 %) 21 (35.6 %)
Household income Less than 60,000/year 14 (51.9 %) 25 (42.4 %) 0.672 0.413
More than 60,000/year 13 (48.1 %) 34 (57.6 %)
Smoking history No 16 (59.3 %) 47 (79.7 %) 4.345 0.114
Less than 20/day 5 (18.5 %) 4 (6.8 %)
More than 20/day 6 (22.2 %) 8 (16.3 %)
Drinking history(per day) No 21 (77.78 %) 52 (88.14 %) 0.330*
Yes 6 (22.22 %) 7 (11.86 %)
History of caffeine intake No 22 (81.48 %) 52 (88.14 %) 0.505*
Yes 5 (18.52 %) 7 (11.86 %)
Other drug history and substance addiction No 21 (77.8 %) 50 (84.7 %) 0.542*
Yes 6 (22.2 %) 9 (15.3 %)
Family history of headache No 12 (44.4 %) 23 (39.0 %) 0.229 0.632
Yes 15 (55.6 %) 36(61.0 %)
MOH family history No 24 (88.9 %) 57 (96.6 %) 0.176*
Yes 3 (11.1 %) 2 (3.4 %)
Family history of addiction to other drugs and
substances
No 22 (81.5 %) 52 (88.1 %) 0.505*
Yes 5 (18.5 %) 7 (11.9 %)
Figures in brackets as a percentage. *For Fisher’s exact test
Yan et al. BMC Neurology  (2015) 15:168 Page 3 of 7
MOH characteristics before drug withdrawal
Medication overuse over time of the case group was
found to be significantly higher (P = 0.037) than that of
the control group (Table 2). The headache frequency of
the case group was markedly (P = 0.035) higher than that
of the control group. There was no significant difference
in the degree of headache pain episodes (P = 0.127) and
duration of each attack (t = 1.646, P = 0.103) between the
two groups.
Characteristics of primary headache
From the 86 patients, 82 (95.4 %) and four (4.65 %) pa-
tients had primary headache that was migraine and
tension-type headache respectively. From the 27 patients
in the case group, 25 (92.6 %) and two (7.4 %) patients
had primary headache that was migraine and tension-type
headache respectively. From the 59 patients in the control
group, 57 (96.6 %) and two (3.4 %) patients had primary
headache that was migraine and tension-type headache.
There was no statistical difference (P = 0.587) in the type
of primary headache between the two groups. There was,
however, a significant difference in the course of pri-
mary headache (P < 0.001) and primary headache fre-
quency (P = 0.007) between the two groups. There was
no significant difference between the two groups for
the degree of primary headache (P = 0.058) and the dur-
ation of each episode (P = 0.055) (Table 3).
Overuse of drugs
There was no significant difference in the overuse of
drugs in the case group and the control group—whether
only a single component of acute medication was used
or whether a compound preparation or analgesic were
used (Table 4).
Drug use and withdrawal situation
Table 5 showed that there was no significant difference
in the frequency of acute medication use (P = 0.051) and
the duration of each episode (P = 0.270) between the
case group and the control group. After drug with-
drawal, headache frequency was significantly higher in
the case group (P < 0.001), headache degree was also
higher than the control group (P = 0.024).
Comorbidity after drug withdrawal
There was no significant difference between the case
group and the control group for comorbidity after drug
withdrawal, including sleep disorders (P = 0.139), anxiety
(P = 0.254), depression (P = 1.000) and other discomfort
(P = 0.221) (Table 6).
Prevention of drug use
All 86 patients underwent drug treatment to prevent
headache after drug withdrawal. There was a significant
difference (P = 0.009) in the timeframe for the application
of drug prevention between the two groups (Table 7).
Risk factors for preliminary screening
Seven risk factors were screened through the analysis of
the 31 factors (such as age; P < 0.05), including medication
overuse over time, headache frequency before drug with-
drawal, duration of primary headache, primary headache
frequency, headache frequency after drug withdrawal, se-
verity of headache after drug withdrawal, and the time-
frame for the application of drug prevention (Table 8).
Multivariate analysis
Multi-factor unconditional logistic regression analysis was
carried on medication overuse over time, headache fre-
quency before drug withdrawal, duration of primary head-
ache, primary headache frequency, headache frequency
Table 2 MOH characteristics before drug withdrawal
Indicators Case group Control group Statistic P
Medication overuse over time(year) 4.04 ± 1.126 3.37 ± 1.731 t = 2.124 0.037
Headache frequency (days/month) 24.07 ± 4.811 21.76 ± 4.573 t = 2.140 0.035
The degree of headache (VAS) 6 ~ 9 (8) 6 ~ 9 (8) Z = −1.528 0.127
Duration of each attack (h) 10.15 ± 6.707 7.90 ± 5.473 t = 1.646 0.103
Normal distribution data with‾x ± s, statistics as the t value; Skewed distribution data with poor and median (in parentheses), statistics as the z value.
Table 3 Characteristics of primary headache
Indicators Case group Control group Statistic P
Course of primary headache 10 ~ 45 (20) 2 ~ 35 (8) Z = −5.973 < 0.001
Headache frequency (days/month) 8.70 ± 2.072 7.12 ± 2.607 t = 2.780 0.007
Duration of each attack (h) 1 ~ 6 (3) 1 ~ 12 (2) Z = −1.922 0.055
Headache degree (VAS) 6.22 ± 1.050 5.78 ± 0.966 t = 1.918 0.058
Normal distribution data with‾x ± s, statistics as the t value; Skewed distribution data with poor and median (in parentheses), statistics as the z value
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after drug withdrawal, severity of headache after drug
withdrawal, and the timeframe for the application of drug
prevention. Three indicators (headache frequency before
drug withdrawal, duration of primary headache, and head-
ache frequency after drug withdrawal) were applied to the
regression equation and were found to be independent
risk factors for MOH relapse (Table 9).
Discussion
A recent number of international clinical studies on the
long-term prognosis of MOH have revealed that MOH
has a high relapse rate, with 30–45 % of MOH patients
relapsing after withdrawal and a 1-year relapse rate of
22–44 % [7]. In some large-scale clinical follow-ups of a
6-year long-term prognosis, patients experience a relapse
rate of 24–43 %, with the majority of relapse cases oc-
curring within a year after withdrawal [9]. Despite these
findings, no such research has been undertaken in China
and thus, MOH relapse rate and independent risk fac-
tors remain unknown for this country.
The present study involved a total of 86 MOH patients
with complete data and who met the conditions, and were
followed up 2 months after withdrawal. Our findings
showed no significant difference between two groups re-
garding demographic and sociological characteristics.
These results corroborate those of Zidverc-Trajkovic et al.
[10, 11]. However, a study by Sances et al. [12] believes
that heavy smoking and drinking may increase the relapse
rate in the first year, most likely due to the effect of psy-
choactive substances (such as alcohol, tobacco, and
opium) in patients with addictive substance abuse. Pa-
tients with a high risk of suffering from MOH are more
susceptible to drug dependence and are more likely to re-
lapse after withdrawal [13].
In the present study, medication overuse overtime and
headache frequency in the case group were significantly
higher than those of the control group when examining
MOH characteristics before drug withdrawal. When the
regression equation was applied to headache frequency
before drug withdrawal, it was found to be an independ-
ent risk factor for MOH relapse. Our results indicated
that the higher the headache frequency prior to drug
withdrawal, the higher the relapse after drug withdrawal.
A significant difference was found between the two
groups for primary headache and primary headache fre-
quency. The regression equation analysis revealed that
primary headache frequency was another independent
risk factor for MOH relapse and that an increase in re-
lapse was associated with high-frequency primary head-
ache. These findings are consistent with those of Sances
et al. [12] who has shown that primary headache fre-
quency is an independent risk factor that affects the out-
come of MOH treatment.
Our results also showed that the overuse of drugs was
not significantly different between the two groups. Stud-
ies have shown that the MOH relapse rate is the lowest
with acute use of ergot amines, and triptans drugs have
a significantly lower (21 %) effect than analgesic drugs
(71 %), composite analgesics, and barbiturates (e.g.
butalbital) [14]. Opioids are also most likely to cause
MOH relapse [11].
Headache frequency and headache degree were signifi-
cantly different between the two groups after drug with-
drawal. The MOH regression analysis for headache






Use only a single
component drug
9 (33.3 %) 14 (23.7 %) 0.872 0.350
Use only NSAID 6 (22.2 %) 10 (17.0 %) 0.340 0.560
Use only Chinese patent
medicine
3 (11.1 %) 3 (5.1 %) 0.373*
Use only benzodiazepines 0 1 (1.7 %) 1.000*
Combination of compound
preparations or painkillers
18 (66.7 %) 45 (76.23 %) 0.872 0.350
Figures in brackets as a percentage. *For Fisher’s exact test
Table 5 Drug use and withdrawal situation
Indicators Case group Control group Statistic P
Drug use frequency
(days/month)




7.67 ± 1.961 3.42 ± 1.499 t = 11.026 < 0.001
Duration of each
attack (h)




5.52 ± 1.341 4.85 ± 0.943 t = 2.348 0.024
Normal distribution data with‾x ± s, statistics as the t value; Skewed distribution
data with poor and median (in parentheses), statistics as the z value






Sleep disorders 17 (62.96 %) 27(45.76 %) 2.193 0.139
Anxiety 8 (29.63 %) 11(18.64 %) 1.299 0.254
Depression 0 (0 %) 1 (1.70 %) 1.000*
Other symptoms 7 (25.9 %) 8 (13.6 %) 0.221*
Figures in brackets as a percentage. *For Fisher’s exact test








< 6 months 11 (40.74 %) 9 (15.25 %) 6.742 0.009
> 6 months 16 (59.26 %) 50 (84.75 %)
Yan et al. BMC Neurology  (2015) 15:168 Page 5 of 7
frequency revealed that it was the most important inde-
pendent risk factor to affect relapse, thereby indicating
that the higher the headache frequency after drug with-
drawal, the more likely that the MOH patient will re-
lapse. Rossi et al. [11] have shown that patients with
high frequency of headache after withdrawal are at
higher risk of MOH relapse. Other studies have con-
firmed that after a successful drug withdrawal and a 3-
month drug prevention treatment, 60 % of the chronic
migraine patients with headache frequency greater than
10 days/month re-develop MOH [15].
After drug withdrawal, there was no significant differ-
ence in MOH comorbidity between the two groups. There
was a significant difference in the timeframe for the appli-
cation of drug prevention drug between two groups, but
the MOH regression equation was not used for this index.
The purpose of preventive treatment was to reduce the
frequency of headache to decrease the frequency of taking
drugs. Reducing headache frequency may decrease mood
swings during headache as well as reduce the early use of
medication prevent headache. As MOH relapse rate is
high, preventive treatment is best carried out long-term.
Headache frequency of drug withdrawal, duration of pri-
mary headache, and headache frequency after drug with-
drawal were the three factors screened out to be
independent risk factors for MOH relapse in the follow-up
of the 86 patients. However, there were some limitations of
this study: (1) The sample size was small, (2) patients who
were diagnosed with short-term (every 3 months/time)
MOH were not followed up continuously, and (3) dynamic
tracking was not applied. Therefore, there may have been
some bias regarding the return visit data, and this should
be avoided in future studies.
To prevent MOH relapse, drug dependence screening
using questionnaires in patients with primary headache in
clinical routing becomes particularly important. Clinicians
find that the patients’ tendency for drug dependence pre-
vents the occurrence of MOH. In the 2011 International
Headache Conference, the majority of experts agreed that
MOH patients should discontinue drug overuse (with-
drawal treatment) [16]. Preventing the overuse of drugs
can relieve headaches or completely eradicate them, as
well as enhance the efficacy of preventive drugs. Because
withdrawal reactions may occur after the withdrawal of
certain drugs—particularly benzodiazepines—and other
drugs such as opiates and barbiturates, patients taking
these drugs should withdraw from them slowly and grad-
ually. Topiramate and a local injection of onabotulinum-
toxinA have been shown to exhibit the same efficacy as
therapeutic agents for re-prophylaxis after detoxification
in chronic migraine patients with or without medication
overuse [17, 18]. Grande et al. [19] have shown that cogni-
tive behavior therapy (psychotherapy combined with drug
therapy) is more effective in improving headache and the
quality of life of patients. Prophylactic pharmacologic
measures as well as psychological support, education, and
surveillance to prevent relapses are considered to enhance
the chances of success in MOH relapse [20]. In recent
years, MOH patients have had a high risk of relapse, and
this relapse rate is too high. Therefore, clinicians need to
develop effective relapse prevention strategies to effect-
ively reduce the MOH relapse rate.
Conclusion
MOH relapse in China may be related to three risk fac-
tors: headache frequency before drug withdrawal, duration
of primary headache, and headache frequency after drug
withdrawal.
Table 8 Risk factors for preliminary screening
Indicators Statistics P
Medication overuse time t = 2.124 0.037
Headache frequency before drug withdrawal t = 2.140 0.035
Duration of primary headache Z = −5.973 < 0.001
Primary headache frequency t = 2.780 0.007
Headache frequency after drug withdrawal t = 11.026 < 0.001
Severity of headache after drug withdrawal t = 2.348 0.024
Application time of prevention drug χ2 = 6.742 0.009
Table 9 Multi-factor unconditioned Logistic regression analysis results
Name of factors B S.E. Wals Df Sig. Exp (B) EXP(B)的 95 % C.I.
lower limit upper limit
Years of medication overuse 1.541 1.055 2.131 1 0.144 4.669 0.590 36.953
Headache frequency before drug withdrawal 0.559 0.271 4.237 1 0.040 1.748 1.027 2.976
Frequency of Primary headache 0.543 0.511 1.130 1 0.288 1.721 0.633 4.683
Duration of primary headache 0.226 0.114 3.930 1 0.047 1.254 1.003 1.567
Headache frequency after drug withdrawal 3.078 1.351 5.192 1 0.023 21.721 1.538 306.780
Severity of headache after drug withdrawal -.830 1.002 0.686 1 0.407 0.436 0.061 3.107
Application time of prevention drug −1.445 1.591 0.825 1 0.364 0.236 0.010 5.331
Constant −38.412 19.384 3.927 1 0.048 0.
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